Document text
Principal Investigator: Steven Holland
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $19,619
Funding agency: National Institute of Allergy and Infectious Diseases
For Autoantibody study, patient samples from the COVID-19 cohort obtained by Dr. Notarangelo, and control samples, were comprehensively screened for the presence of anticytokine autoantibodies. Functional studies were also performed to verify if positive samples contained neutralizing antibodies. We found that approximately 10% of patients with severe COVID-19 had high levels fo neutralizing antibodies against type I interferons. A manuscript describing these results was published in Science.
For COVID-19 surveillance, a new clinical protocol was initiated at the NIH Clinical Center (20-I-0117). This is a prospective longitudinal cohort study of individuals with exposure to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The aim is to correlate results of reverse transcription-polymerase chain reaction (RT-PCR) using various sample types, assays, and culture. We will perform serial screenings of NIH employees who have had contact with reported, suspected or known cases. We will also enroll individuals with previous or current infection who are asymptomatic at enrollment. The serial screenings will be done at multiple timepoints over 28 days using RT-PCR tests of nasopharyngeal (NP) swabs, saliva samples, midturbinate swabs, antibody assays and culture. Enrollment on this protocol has been paused with the decline in severe cases here.
Terms: <Assay><Autoantibodies><Bioassay><Biological Assay><COVID infected patient><COVID patient><COVID positive patient><COVID surveillance><COVID-19><COVID-19 exposure><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 surveillance><COVID-19 virus infection><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 surveillance><CV-19><Clinical Protocols><Coronavirus Infectious Disease 2019><Country><Disease Outcome><Employee><Enrollment><Goals><Individual><Infection><Interferon Type I><Italy><Long-term cohort study><Longitudinal cohort study><Longterm cohort study><Manuscripts><NIH><National Institutes of Health><Patients><Polymerase Chain Reaction><Protocol><Protocols documentation><Publishing><Reporting><Reverse Transcription><SARS-CoV-2 exposure><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 surveillance><SARS-CoV2 exposure><SARS-CoV2 infection><Sampling><Science><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severity of illness><Swab><Testing><United States National Institutes of Health><antibody assay><antibody based test><antibody test><autoimmune antibody><autoreactive antibody><clinical center><cohort><coronavirus disease 2019><coronavirus disease 2019 exposure><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 surveillance><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease surveillance><coronavirus disease-19><coronavirus disease-19 patient><coronavirus infectious disease-19><coronavirus patient><cytokine><disease severity><enroll><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><nasopharyngeal swab><neutralizing antibody><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><prospective><saliva sample><salivary sample><screening><screenings><self reactive antibody><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 surveillance><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2>